KR20200135465A - Cgrp 관련 장애를 위한 리메게판트 - Google Patents

Cgrp 관련 장애를 위한 리메게판트 Download PDF

Info

Publication number
KR20200135465A
KR20200135465A KR1020207030358A KR20207030358A KR20200135465A KR 20200135465 A KR20200135465 A KR 20200135465A KR 1020207030358 A KR1020207030358 A KR 1020207030358A KR 20207030358 A KR20207030358 A KR 20207030358A KR 20200135465 A KR20200135465 A KR 20200135465A
Authority
KR
South Korea
Prior art keywords
limegepant
pharmaceutical composition
placebo
migraine
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207030358A
Other languages
English (en)
Korean (ko)
Inventor
블라디미르 코릭
로버트 크룹
Original Assignee
바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68060723&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20200135465(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. filed Critical 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디.
Publication of KR20200135465A publication Critical patent/KR20200135465A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020207030358A 2018-03-25 2019-03-25 Cgrp 관련 장애를 위한 리메게판트 Ceased KR20200135465A (ko)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862647794P 2018-03-25 2018-03-25
US62/647,794 2018-03-25
US201862664761P 2018-04-30 2018-04-30
US62/664,761 2018-04-30
US201862774285P 2018-12-02 2018-12-02
US62/774,285 2018-12-02
US201862777180P 2018-12-09 2018-12-09
US62/777,180 2018-12-09
US201862777625P 2018-12-10 2018-12-10
US62/777,625 2018-12-10
PCT/US2019/023940 WO2019191008A1 (en) 2018-03-25 2019-03-25 Rimegepant for cgrp related disorders

Publications (1)

Publication Number Publication Date
KR20200135465A true KR20200135465A (ko) 2020-12-02

Family

ID=68060723

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207030358A Ceased KR20200135465A (ko) 2018-03-25 2019-03-25 Cgrp 관련 장애를 위한 리메게판트

Country Status (19)

Country Link
US (3) US20210000814A1 (enExample)
EP (3) EP4088720B1 (enExample)
JP (2) JP2021519288A (enExample)
KR (1) KR20200135465A (enExample)
CN (1) CN112153969A (enExample)
AU (1) AU2019242604B2 (enExample)
BR (1) BR112020019396A2 (enExample)
CA (1) CA3094693A1 (enExample)
DK (1) DK4088720T3 (enExample)
ES (1) ES3047659T3 (enExample)
FI (1) FI4088720T3 (enExample)
IL (1) IL277272B1 (enExample)
MX (1) MX2020009856A (enExample)
PH (1) PH12020551425A1 (enExample)
PL (1) PL4088720T3 (enExample)
PT (1) PT4088720T (enExample)
SG (1) SG11202009199YA (enExample)
WO (1) WO2019191008A1 (enExample)
ZA (2) ZA202006190B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202009199YA (en) * 2018-03-25 2020-10-29 Biohaven Pharm Holding Co Ltd Rimegepant for cgrp related disorders
JP2022517433A (ja) * 2019-01-20 2022-03-08 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッド 突出性の片頭痛を処置するためのｃｇｒｐアンタゴニスト
EP4076395A4 (en) * 2019-12-17 2024-02-07 Pfizer Ireland Pharmaceuticals INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS
MX2022010407A (es) * 2020-02-27 2022-11-07 Biohaven Pharm Holding Co Ltd Forma de dosis oral de rápida dispersión de rimegepant.
CA3176072A1 (en) * 2020-03-23 2021-09-30 Biohaven Pharmaceutical Holding Company Ltd. Methods of treating pulmonary injury with cgrp inhibitors
JP2023533634A (ja) * 2020-03-29 2023-08-04 バイオヘイブン・ファーマシューティカル・アイルランド・デジグネイテッド・アクティビティ・カンパニー 片頭痛の予防的治療
WO2022103636A1 (en) 2020-11-16 2022-05-19 Orcosa Inc. Improved use of cannabinoids in the treatment of alzheimer's disease
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
KR20230088442A (ko) * 2020-11-19 2023-06-19 화이자 아일랜드 파마슈티컬즈 Cgrp 억제제의 개선된 전달을 위한 조성물
CN116456981A (zh) * 2020-11-19 2023-07-18 辉瑞爱尔兰制药公司 用于改善的grp抑制剂递送的组合物
WO2022251752A2 (en) * 2021-05-25 2022-12-01 Biohaven Pharmaceutical Ireland Dac Dual treatment of migraine
CN115850266A (zh) * 2021-09-26 2023-03-28 奥锐特药业(天津)有限公司 瑞美吉泮新晶型及其制备方法
WO2023055758A1 (en) * 2021-09-29 2023-04-06 Pfizer Ireland Pharmaceuticals Preventative treatment of migraine
CN114010608A (zh) * 2021-11-23 2022-02-08 莱默(北京)药业科技有限公司 一种瑞美吉泮冻干口崩片及制备方法
CN115154469A (zh) * 2022-07-22 2022-10-11 中国科学院广州生物医药与健康研究院 瑞美吉泮或其药学上可接受的盐在制备预防或治疗肥胖的药物中的应用
WO2024062504A1 (en) * 2022-09-22 2024-03-28 Quisitive Therapeutics Pharmaceutical composition comprising ubrogepant and administration thereof
WO2024211881A1 (en) * 2023-04-06 2024-10-10 Navinta, Llc Rimegepant suspension
WO2024220974A1 (en) * 2023-04-21 2024-10-24 Navinta, Llc Rimegepant fast-dissolving films for oral administration
CN117414352A (zh) * 2023-11-22 2024-01-19 湖北广济医药科技有限公司 一种瑞美吉泮口溶膜剂及其制备方法
WO2025193980A2 (en) * 2024-03-13 2025-09-18 CNS Biosciences, Inc. Method of treating neuropathic pain using an anti-cgrp inhibitor

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US7704583B2 (en) 1998-08-14 2010-04-27 R.P.Scherer Technologies, Inc. Embossed blister pack
GB9817793D0 (en) 1998-08-14 1998-10-14 Scherer Corp R P The formation of indicia in the base of a blister pack for transference to a body cast therein
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
EP1912653B1 (en) * 2005-07-29 2014-01-01 Merck Sharp & Dohme Corp. Heterocyclic benzodiazepine cgrp receptor antagonists
US8715715B2 (en) * 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
US8314117B2 (en) 2009-10-14 2012-11-20 Bristol-Myers Squibb Company CGRP receptor antagonists
US8669368B2 (en) 2010-10-12 2014-03-11 Bristol-Myers Squibb Company Process for the preparation of cycloheptapyridine CGRP receptor antagonists
ES2746031T3 (es) 2012-02-27 2020-03-04 Bristol Myers Squibb Co Sal de N-(5S,6S,9R)-5-amino-6-(2,3-difluorofenil)-6,7,8,9-tetrahidro-5H-ciclohepta[B]piridin-9-IL-4-(2-oxo-2,3-dihidro-1H-imidazo[4,5-B]piridin-1-il)piperidina-1-carboxilato
US20130225336A1 (en) * 2012-02-28 2013-08-29 Edward R. Harvey Method and apparatus for teaching the throwing of a curveball without injury
EP2815749A1 (en) * 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
RU2019123406A (ru) * 2014-02-05 2019-10-03 Мерк Шарп И Доум Корп. Технология приготовления таблеток для cgrp-активных соединений
CA2921336A1 (en) * 2015-06-30 2016-12-30 Gilead Sciences, Inc. Pharmaceutical formulations
GB201519196D0 (en) * 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
SG11202009199YA (en) * 2018-03-25 2020-10-29 Biohaven Pharm Holding Co Ltd Rimegepant for cgrp related disorders
JP2022517433A (ja) * 2019-01-20 2022-03-08 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッド 突出性の片頭痛を処置するためのｃｇｒｐアンタゴニスト

Also Published As

Publication number Publication date
EP4088720A1 (en) 2022-11-16
ZA202204929B (en) 2024-10-30
ZA202006190B (en) 2025-07-30
IL277272B1 (en) 2024-09-01
US20200383969A1 (en) 2020-12-10
WO2019191008A1 (en) 2019-10-03
EP4088720B1 (en) 2025-09-03
EP4631944A3 (en) 2025-12-24
IL277272A (en) 2020-10-29
EP3773572A4 (en) 2022-01-05
ES3047659T3 (en) 2025-12-04
CA3094693A1 (en) 2019-10-03
US20210000814A1 (en) 2021-01-07
SG11202009199YA (en) 2020-10-29
PT4088720T (pt) 2025-10-15
CN112153969A (zh) 2020-12-29
JP2021519288A (ja) 2021-08-10
US20220168295A1 (en) 2022-06-02
MX2020009856A (es) 2020-10-08
PL4088720T3 (pl) 2025-12-15
AU2019242604A1 (en) 2020-10-22
BR112020019396A2 (pt) 2021-01-05
US11083724B2 (en) 2021-08-10
PH12020551425A1 (en) 2021-12-13
DK4088720T3 (da) 2025-09-29
JP2023134690A (ja) 2023-09-27
EP3773572A1 (en) 2021-02-17
FI4088720T3 (fi) 2025-11-14
EP4631944A2 (en) 2025-10-15
AU2019242604B2 (en) 2025-01-02

Similar Documents

Publication Publication Date Title
US11083724B2 (en) Rimegepant for CGRP related disorders
US20210196699A1 (en) Cgrp antagonists for treating migraine breakthrough
EP4125881B1 (en) New use of angiotensin ii type 2 receptor agonist
US20230108049A1 (en) Oral fast-dispersing dosage form of rimegepant
CA3176432A1 (en) Preventative treatment of migraine
EA045801B1 (ru) Фармацевтическая композиция римегепанта в форме быстродиспергирующейся пероральной лекарственной формы
US20220233480A1 (en) Use of angiotensin ii type 2 receptor agonist
US20230285380A1 (en) Dual treatment of migraine
WO2023055758A1 (en) Preventative treatment of migraine
HK40083616A (en) Oral fast-dispersing dosage form of rimegepant

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902